$SMLR
Semler Scientific, Inc.

2024 Q1 Form 10-K Financial Statement

#000155485924000010 Filed on March 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $15.90M $15.06M $68.18M
YoY Change -12.65% 9.15% 20.28%
Cost Of Revenue $1.247M $3.385M $6.984M
YoY Change -1.73% 186.38% 64.25%
Gross Profit $14.66M $11.67M $61.20M
YoY Change -13.47% -7.46% 16.72%
Gross Profit Margin 92.16% 77.52% 89.76%
Selling, General & Admin $6.542M $7.943M $32.44M
YoY Change -27.72% 4.09% 6.62%
% of Gross Profit 44.64% 68.05% 53.0%
Research & Development $1.138M $1.207M $5.421M
YoY Change -30.18% -11.58% 12.73%
% of Gross Profit 7.76% 10.34% 8.86%
Depreciation & Amortization $176.0K $160.0K $599.0K
YoY Change 36.43% 25.98% 1.7%
% of Gross Profit 1.2% 1.37% 0.98%
Operating Expenses $6.542M $9.150M $37.86M
YoY Change -27.72% 1.71% 24.44%
Operating Profit $6.976M $2.522M $22.26M
YoY Change 11.51% -30.27% 29.37%
Interest Expense $819.0K $609.0K $2.164M
YoY Change 117.24% 77.55% 338.06%
% of Operating Profit 11.74% 24.15% 9.72%
Other Income/Expense, Net $821.0K $20.00K $1.844M
YoY Change 117.77% -766.67% 277.1%
Pretax Income $7.797M $2.814M $24.10M
YoY Change 17.55% -28.89% 36.22%
Income Tax $1.724M -$1.407M $3.517M
% Of Pretax Income 22.11% -50.0% 14.59%
Net Earnings $6.073M $4.221M $20.58M
YoY Change 22.22% 31.25% 43.69%
Net Earnings / Revenue 38.19% 28.03% 30.19%
Basic Earnings Per Share $0.88 $3.06
Diluted Earnings Per Share $0.78 $0.55 $2.63
COMMON SHARES
Basic Shares Outstanding 7.031M 6.873M 6.733M
Diluted Shares Outstanding 7.782M 7.819M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.75M $57.20M $57.20M
YoY Change 46.05% 32.75% 32.75%
Cash & Equivalents $62.75M $57.20M
Short-Term Investments
Other Short-Term Assets $2.611M $2.174M $2.174M
YoY Change -5.71% 48.09% 48.09%
Inventory $408.0K $445.0K $445.0K
Prepaid Expenses
Receivables $6.132M $6.125M $6.125M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $71.91M $65.94M $65.94M
YoY Change 29.34% 34.83% 34.83%
LONG-TERM ASSETS
Property, Plant & Equipment $2.849M $3.155M $3.155M
YoY Change -24.79% -6.6% -6.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.884M $5.884M $5.884M
YoY Change -0.15% 6.98% 6.98%
Other Assets $249.0K $270.0K $3.082M
YoY Change -91.16% -90.5% -37.19%
Total Long-Term Assets $11.95M $12.12M $12.12M
YoY Change -18.51% -12.07% -12.07%
TOTAL ASSETS
Total Short-Term Assets $71.91M $65.94M $65.94M
Total Long-Term Assets $11.95M $12.12M $12.12M
Total Assets $83.86M $78.07M $78.07M
YoY Change 19.36% 24.52% 24.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $410.0K $402.0K $402.0K
YoY Change 37.58% -51.86% -51.86%
Accrued Expenses $4.305M $4.502M $4.592M
YoY Change -40.26% -5.18% -4.99%
Deferred Revenue $996.0K $1.120M
YoY Change -22.55% -3.45%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.903M $6.200M $6.200M
YoY Change -33.81% -9.58% -9.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $47.00K $70.00K $70.00K
YoY Change -65.94% -56.25% -56.25%
Total Long-Term Liabilities $47.00K $70.00K $70.00K
YoY Change -65.94% -56.25% -56.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.903M $6.200M $6.200M
Total Long-Term Liabilities $47.00K $70.00K $70.00K
Total Liabilities $5.950M $6.270M $6.270M
YoY Change -34.3% -10.65% -10.65%
SHAREHOLDERS EQUITY
Retained Earnings $65.88M $59.80M
YoY Change 49.08% 52.48%
Common Stock $7.000K $7.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.91M $71.80M $71.80M
YoY Change
Total Liabilities & Shareholders Equity $83.86M $78.07M $78.07M
YoY Change 19.36% 24.52% 24.52%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $6.073M $4.221M $20.58M
YoY Change 22.22% 31.25% 43.69%
Depreciation, Depletion And Amortization $176.0K $160.0K $599.0K
YoY Change 36.43% 25.98% 1.7%
Cash From Operating Activities $5.624M $4.442M $21.33M
YoY Change 553.19% 159.77% 22.14%
INVESTING ACTIVITIES
Capital Expenditures $4.000K -$255.0K $345.0K
YoY Change -95.79% -131.44% -27.52%
Acquisitions
YoY Change
Other Investing Activities $18.37M $19.22M
YoY Change -178.2% -177.91%
Cash From Investing Activities -$81.00K $18.63M $18.40M
YoY Change -99.56% -176.64% -168.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.00K -3.236M -5.408M
YoY Change -107.53% -4414.67% 9.54%
NET CHANGE
Cash From Operating Activities 5.624M 4.442M 21.33M
Cash From Investing Activities -81.00K 18.63M 18.40M
Cash From Financing Activities 11.00K -3.236M -5.408M
Net Change In Cash 5.554M 19.83M 34.32M
YoY Change -131.36% -188.07% -339.84%
FREE CASH FLOW
Cash From Operating Activities $5.624M $4.442M $21.33M
Capital Expenditures $4.000K -$255.0K $345.0K
Free Cash Flow $5.620M $4.697M $20.99M
YoY Change 633.68% 422.47% 23.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001554859
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2023 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
734000
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36305
CY2023 dei Entity Registrant Name
EntityRegistrantName
SEMLER SCIENTIFIC, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1367393
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2340-2348 Walsh Avenue, Suite 2344
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95051
CY2023 dei City Area Code
CityAreaCode
877
CY2023 dei Local Phone Number
LocalPhoneNumber
774-4211
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
SMLR
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
114785516
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7031083
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
243
CY2023 dei Auditor Name
AuditorName
BDO USA, P.C.
CY2023 dei Auditor Location
AuditorLocation
New York, NY
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57200000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23014000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
132000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
20073000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
287000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
109000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6125000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3884000
CY2023Q4 us-gaap Inventory Net
InventoryNet
445000
CY2022Q4 us-gaap Inventory Net
InventoryNet
469000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2042000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1468000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
65944000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
48908000
CY2023Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
2285000
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
2478000
CY2023Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
720000
CY2022Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
667000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
512000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
821000
CY2023Q4 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
4372000
CY2022Q4 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
3679000
CY2023Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
5372000
CY2022Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
4679000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
270000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2842000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2962000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2298000
CY2023Q4 us-gaap Assets
Assets
78065000
CY2022Q4 us-gaap Assets
Assets
62693000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
402000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
835000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4502000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4748000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1120000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1160000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
176000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
114000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6200000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6857000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
70000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
160000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
70000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
160000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7099441
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6906544
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6885019
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6692122
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
214422
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
214422
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11985000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
16449000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
59803000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
39220000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
71795000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
55676000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78065000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62693000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68184000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56686000
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
6984000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
4252000
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
5773000
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
4809000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18147000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17685000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14290000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12737000
CY2023 us-gaap Restructuring Charges
RestructuringCharges
734000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
45928000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
39483000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
22256000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
17203000
CY2023 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2471000
CY2022 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
494000
CY2023 smlr Impairment Losses Investments
ImpairmentLossesInvestments
337000
CY2023 smlr Fair Value Adjustment Of Notes Held For Investment
FairValueAdjustmentOfNotesHeldForInvestment
307000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1844000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
489000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
24100000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17692000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3517000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3367000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
20583000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
14325000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.06
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.13
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6732806
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6726687
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.63
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.79
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7819159
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7999750
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
4991000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
723000
CY2022 smlr Taxes Paid Related To Net Share Settlement Of Equity Awards
TaxesPaidRelatedToNetShareSettlementOfEquityAwards
-114000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
168000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
14325000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
55676000
CY2023 smlr Adjustments To Additional Paid In Capital Repurchase Of Warrants
AdjustmentsToAdditionalPaidInCapitalRepurchaseOfWarrants
1949000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
860000
CY2023 smlr Taxes Paid Related To Net Share Settlement Of Equity Awards
TaxesPaidRelatedToNetShareSettlementOfEquityAwards
-3510000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
84000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
20583000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
71795000
CY2023 us-gaap Profit Loss
ProfitLoss
20583000
CY2022 us-gaap Profit Loss
ProfitLoss
14325000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
599000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
589000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-664000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-351000
CY2023 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-369000
CY2022 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-463000
CY2023 smlr Prepaid License Purchases Writeoff
PrepaidLicensePurchasesWriteoff
2476000
CY2023 us-gaap Debt Securities Trading Realized Gain
DebtSecuritiesTradingRealizedGain
151000
CY2022 us-gaap Debt Securities Trading Realized Gain
DebtSecuritiesTradingRealizedGain
77000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
268000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
103000
CY2023 smlr Fair Value Adjustment Of Notes Held For Investment
FairValueAdjustmentOfNotesHeldForInvestment
307000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
944000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
741000
CY2023 smlr Impairment Losses Investments
ImpairmentLossesInvestments
337000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2508000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
367000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-24000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-81000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
603000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2576000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-96000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2510000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-433000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
392000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-246000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1310000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-68000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
188000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21330000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
17463000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
345000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
476000
CY2023 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1000000
CY2023 smlr Proceeds From Payment For Short Term Investments
ProceedsFromPaymentForShortTermInvestments
-78093000
CY2022 smlr Proceeds From Payment For Short Term Investments
ProceedsFromPaymentForShortTermInvestments
4679000
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57869000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19996000
CY2023 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
483000
CY2022 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
1684000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18396000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26835000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3510000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
114000
CY2023 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
1949000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4991000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
168000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5408000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4937000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34318000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14309000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23014000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37323000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57332000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23014000
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
4060000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
2400000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.    The Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Semler Scientific Inc. (the “Company”) is a company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. The Company’s mission is to develop, manufacture and market innovative products and services that assist our customers in evaluating and treating chronic diseases. The Company’s patented and U.S. Food and Drug Administration (“FDA”), cleared product, QuantaFlo, measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (“PAD”). The Company is currently seeking a new 510(k) clearance from the FDA for the expanded use of QuantaFlo, which is intended to enable expanded labeling as an aid in the diagnosis of other cardiovascular diseases in addition to PAD.</p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses, and related disclosures during the reporting period. Significant items subject to such estimates include allowance for credit losses, valuation of equipment on lease, recognition and measurement of current and deferred income taxes, valuation and recognition of investments and valuation of inventory. These estimates and assumptions are based on management’s best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from these estimates.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, restricted cash, accounts receivable and trade payables. The Company maintains its cash with major financial institutions. The Company’s cash consists of bank deposits held with banks that, at times, exceed federally insured limits. The cash and cash equivalents also include short term treasury bills with original maturities of three months or less and U.S. government money market fund accounts. The Company manages its accounts receivable credit risk through ongoing credit evaluation of its customers’ financial conditions. The Company generally does not require collateral from its customers. For information regarding the Company’s significant customers and vendors, see Note 11 to financial statements.</p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
287000
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
178000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
109000
CY2023Q4 us-gaap Inventory Net
InventoryNet
445000
CY2023 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
309000
CY2022 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1160000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
921000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5421000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4407000
CY2022Q4 us-gaap Inventory Net
InventoryNet
469000
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2023Q4 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
3375000
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
3702000
CY2023Q4 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1090000
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1224000
CY2023Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
2285000
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
2478000
CY2023 us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
307000
CY2022 us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
386000
CY2023 smlr Assets For Lease Reduction To Accumulated Depreciation
AssetsForLeaseReductionToAccumulatedDepreciation
441000
CY2022 smlr Assets For Lease Reduction To Accumulated Depreciation
AssetsForLeaseReductionToAccumulatedDepreciation
352000
CY2023 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-369000
CY2022 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-463000
CY2023Q4 smlr Assets For Lease Customer Location
AssetsForLeaseCustomerLocation
489000
CY2022Q4 smlr Assets For Lease Customer Location
AssetsForLeaseCustomerLocation
518000
CY2023Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
1544000
CY2022Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
1206000
CY2023Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
824000
CY2022Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
539000
CY2023Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
720000
CY2022Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
667000
CY2023 us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
292000
CY2022 us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
203000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
512000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
821000
CY2023 smlr Percentage Of Probability Of Equity Financing
PercentageOfProbabilityOfEquityFinancing
0.05
CY2023 smlr Percentage Of Probability Of Change Of Control
PercentageOfProbabilityOfChangeOfControl
0.75
CY2023 smlr Percentage Of Probability Of Payment At Maturity Or Insolvency Event
PercentageOfProbabilityOfPaymentAtMaturityOrInsolvencyEvent
0.20
CY2023Q4 us-gaap Debt Securities
DebtSecurities
4372000
CY2022Q4 us-gaap Debt Securities
DebtSecurities
3679000
CY2023Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
5372000
CY2022Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
4679000
CY2023 smlr Debt Security Interest Income
DebtSecurityInterestIncome
449000
CY2022 smlr Debt Security Interest Income
DebtSecurityInterestIncome
20000
CY2022 smlr Debt Security Changes In Fair Value
DebtSecurityChangesInFairValue
0
CY2022Q4 smlr Prepaid Licenses Noncurrent
PrepaidLicensesNoncurrent
2490000
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
270000
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
352000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
270000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2842000
CY2021Q2 smlr Agreement Term
AgreementTerm
P5Y
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
150000
CY2023Q4 smlr Miscellaneous Receivables
MiscellaneousReceivables
100000
CY2023Q4 smlr Long Term Deposits
LongTermDeposits
20000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233000
CY2022Q4 smlr Miscellaneous Receivables
MiscellaneousReceivables
100000
CY2022Q4 smlr Long Term Deposits
LongTermDeposits
19000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2008000
CY2023 us-gaap Variable Lease Income
VariableLeaseIncome
28992000
CY2022 us-gaap Variable Lease Income
VariableLeaseIncome
21277000
CY2023 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
1930000
CY2022 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
1358000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2467000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1991000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1923000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
503000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
358000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4502000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4748000
CY2023 smlr Concentration Risk Credit Risk Exceed Limits
ConcentrationRiskCreditRiskExceedLimits
5465000
CY2023Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
10494000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
41373000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
287000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
109000
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P61M
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.025
CY2023Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y9M
CY2023 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
88000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
88000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
93000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
71000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
164000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
160000
CY2023Q4 smlr Operating Lease Expenses In Excess Of Cash Payments
OperatingLeaseExpensesInExcessOfCashPayments
10000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
150000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
150000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
90000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
70000
CY2023Q4 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2023 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
37262000
CY2022 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
34039000
CY2021Q4 smlr Income Taxes Receivable Cares Act
IncomeTaxesReceivableCaresAct
1240000
CY2021Q4 smlr Income Taxes Receivable Cares Act
IncomeTaxesReceivableCaresAct
1240000
CY2022Q4 smlr Income Taxes Receivable Cares Act
IncomeTaxesReceivableCaresAct
0
CY2023Q4 smlr Income Taxes Receivable Cares Act
IncomeTaxesReceivableCaresAct
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 smlr Number Of Votes For Each Share
NumberOfVotesForEachShare
1
CY2022Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000.0
CY2022 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
148500
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
4991000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1813175
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1548545
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1813175
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1548545
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1287847
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.44
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y10D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
38053000
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
283562
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.36
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
17950
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.52
CY2023 smlr Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y6M10D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
450
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1021785
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.84
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M3D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
41333000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1001344
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.38
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y1M6D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
40964000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0204
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
18048
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
9421
CY2023 smlr Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantDateFairValue
860000
CY2022 smlr Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantDateFairValue
723000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
944000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
741000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
944000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
741000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
3576000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
3201000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
605000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
517000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4181000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3718000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-680000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-373000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
16000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
22000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-664000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-351000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3517000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3367000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0257
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0798
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0403
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0071
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0093
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0024
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0035
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1459
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1896
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
188000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
303000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
268000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
278000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
385000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
529000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
251000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
297000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
262000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
254000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
156000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1450000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
633000
CY2023Q4 smlr Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
38000
CY2022Q4 smlr Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
59000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2998000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2355000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2998000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2355000
CY2023Q4 smlr Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
36000
CY2022Q4 smlr Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
56000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
36000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
56000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
2962000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
2299000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
2607000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
470000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
401000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7999750
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
14325000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.79
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
401000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
476000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
4000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
120000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
65000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
45000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
470000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
401000
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
87000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
30000
CY2023 smlr Research And Experimental Expenditures Capitalized
ResearchAndExperimentalExpendituresCapitalized
4610000
CY2022 smlr Research And Experimental Expenditures Capitalized
ResearchAndExperimentalExpendituresCapitalized
3387000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6732806
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
20583000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.06
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6726687
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14325000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.13
CY2023 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2022 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
68588
CY2022 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1086353
CY2023 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1204475
CY2022 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7819159
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
20583000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.63
CY2023Q3 smlr Restructuring And Related Cost Percentage Of Reduction In Employee Headcount
RestructuringAndRelatedCostPercentageOfReductionInEmployeeHeadcount
0.30
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
734000

Files In Submission

Name View Source Status
0001554859-24-000010-index-headers.html Edgar Link pending
0001554859-24-000010-index.html Edgar Link pending
0001554859-24-000010.txt Edgar Link pending
0001554859-24-000010-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smlr-20231231.xsd Edgar Link pending
smlr-20231231x10k.htm Edgar Link pending
smlr-20231231x10k006.jpg Edgar Link pending
smlr-20231231xex10d7.htm Edgar Link pending
smlr-20231231xex10d7001.jpg Edgar Link pending
smlr-20231231xex10d7004.jpg Edgar Link pending
smlr-20231231xex10d7005.jpg Edgar Link pending
smlr-20231231xex10d7007.jpg Edgar Link pending
smlr-20231231xex10d7008.jpg Edgar Link pending
smlr-20231231xex10d7009.jpg Edgar Link pending
smlr-20231231xex23d1.htm Edgar Link pending
smlr-20231231xex31d1.htm Edgar Link pending
smlr-20231231xex31d2.htm Edgar Link pending
smlr-20231231xex32d1.htm Edgar Link pending
smlr-20231231xex32d2.htm Edgar Link pending
smlr-20231231xex4d2.htm Edgar Link pending
smlr-20231231xex97d1.htm Edgar Link pending
smlr-20231231_def.xml Edgar Link unprocessable
smlr-20231231_lab.xml Edgar Link unprocessable
smlr-20231231_pre.xml Edgar Link unprocessable
smlr-20231231x10k_htm.xml Edgar Link completed
smlr-20231231_cal.xml Edgar Link unprocessable